BACKGROUND:Cancer patients who continue smoking are at increased risk for adverse outcomes including reduced treatment efficacy and poorer survival rates. Many patients spontaneously quit smoking after diagnosis; however, relapse is understudied. The goal of this study was to evaluate smoking-related, affective, cognitive, and physical variables as predictors of smoking after surgical treatment among patients with lung cancer and head and neck cancer. METHODS: A longitudinal study was conducted with 154 patients (57% male) who recently quit smoking. Predictor variables were measured at baseline (ie, time of surgery); smoking behavior was assessed at 2, 4, 6, and 12 months after surgery. Analyses of 7-day point prevalence were performed using a Generalized Estimating Equations approach. RESULTS: Relapse rates varied significantly depending on presurgery smoking status. At 12 months after surgery, 60% of patients who smoked during the week prior to surgery had resumed smoking versus only 13% who were abstinent prior to surgery. Smoking rates among both groups were relatively stable across the 4 follow-ups. For patients smoking before surgery (N ¼ 101), predictors of smoking relapse included lower quitting self-efficacy, higher depression proneness, and greater fears about cancer recurrence. For patients abstinent before surgery (N ¼ 53), higher perceived difficulty quitting and lower cancer-related risk perceptions predicted smoking relapse. CONCLUSIONS: Efforts to encourage early cessation at diagnosis, and increased smoking relapse-prevention efforts in the acute period following surgery, may promote long-term abstinence. Several modifiable variables are identified to target in future smoking relapse-prevention interventions for cancer patients. Cancer 2013;119:1420-7. V C 2012 American Cancer Society.KEYWORDS: tobacco use, smoking relapse, head and neck cancer, lung cancer.
INTRODUCTIONCigarette smoking is responsible for 30% of all cancer-related mortalities. 1 Lung cancers and head and neck cancers are among the malignancies most strongly linked to tobacco use, 1 and a significant proportion of patients with lung cancer and/or head and neck cancer are current smokers at the time of diagnosis. 2,3 Smoking cessation reduces morbidity and mortality in these patients, 4,5 whereas continued smoking after diagnosis increases patients' risk for other smoking-related illnesses (eg, coronary heart disease), second primary tumors, 6,7 and disease recurrence. 5,6 Continued smoking also has more immediate adverse impact, including reduced cancer treatment efficacy, 8,9 higher rates of treatment complications and side effects, 10-13 greater treatment-related weight loss, 14 and poorer quality of life. [15][16][17] The majority of patients smoking at the time of their diagnosis spontaneously quit smoking (eg, 86% among patients with lung cancer 18 ; 84% among patients with head and neck cancer 19 ), with the greatest proportion of quit attempts occurring at diagnosis. 20 Furthermore, smoking cessation interventions for can...